Status
Conditions
Treatments
About
The objectives of this study are to assess the long-term safety and impact on disease activity and progression of natalizumab (Tysabri) in participants with relapsing remitting multiple sclerosis (RRMS) in a clinical practice setting.
Full description
iTOP is a retrospective and prospective Irish observational study of participants receiving natalizumab, with each participant to be followed for 3 years. This study is designed to address the long-term safety profile and the long-term impact on disease activity and progression of natalizumab with marketed use. Collection of efficacy and safety data at 6- monthly intervals to coincide with regular clinic visits and routine clinical practice will therefore be undertaken during the iTOP observational period.
Enrollment
Sex
Volunteers
Inclusion and exclusion criteria
Key Inclusion Criteria:
NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal